49 results  1 of 3 

1 EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
Hongsik Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
Cancer Res Treat.2023;55(2):498-505.   Published online 2022 October 4     DOI: http://dx.doi.org/10.4143/crt.2022.388
      
2 Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
Byoung Chul Cho, Dong-Wan Kim, Ullas Batra, Keunchil Park, Sang-We Kim, Cheng-Ta Yang, Pei-Jye Voon, Virote Sriuranpong, K. Govind Babu, Khalid Amin, Yingbo Wang, Paramita Sen, Khemaies Slimane, Sarayut Geater
Cancer Res Treat.2023;55(1):83-93.   Published online 2022 March 25     DOI: http://dx.doi.org/10.4143/crt.2021.1571
      
3 Selection Strategies and Practical Application of BRAF V600E-Mutated Non–Small Cell Lung Carcinoma
Inwoo Hwang, Yoon-La Choi, Hyunwoo Lee, Soohyun Hwang, Boram Lee, Hobin Yang, Chaithanya Chelakkot, Joungho Han
Cancer Res Treat.2022;54(3):782-792.   Published online 2021 November 23     DOI: http://dx.doi.org/10.4143/crt.2021.843
      
4 The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non–Small Cell Lung Cancer
Noeul Kang, Ki Hwan Kim, Byeong-Ho Jeong, Kyungjong Lee, Hojoong Kim, O Jung Kwon, Myung-Ju Ahn, Jeonghee Cho, Ho Yun Lee, Sang-Won Um
Cancer Res Treat.2022;54(3):817-826.   Published online 2021 November 9     DOI: http://dx.doi.org/10.4143/crt.2021.822
      
5 Usefulness of Pulmonary Rehabilitation in Non–Small Cell Lung Cancer Patients Based on Pulmonary Function Tests and Muscle Analysis Using Computed Tomography Images
Juwhan Choi, Zepa Yang, Jinhwan Lee, Jun Hee Lee, Hyun Koo Kim, Hwan Seok Yong, Sung Yong Lee
Cancer Res Treat.2022;54(3):793-802.   Published online 2021 October 20     DOI: http://dx.doi.org/10.4143/crt.2021.769
      
6 Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non–Small Cell Lung Cancer
Hyun-Seock Shin, Juwhan Choi, Jinhwan Lee, Sung Yong Lee
Cancer Res Treat.2022;54(2):458-468.   Published online 2021 September 10     DOI: http://dx.doi.org/10.4143/crt.2021.425
      
7 Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment
Hongsik Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat.2022;54(1):150-156.   Published online 2021 May 6     DOI: http://dx.doi.org/10.4143/crt.2021.306
      
8 Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report
Dong Won Baek, Yee Soo Chae
Yeungnam Univ J Med.2021;38(4):366-370.   Published online 2021 March 23     DOI: http://dx.doi.org/10.12701/yujm.2021.00899
      
9 The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
Wonyoung Choi, Seog-Yun Park, Youngjoo Lee, Kun Young Lim, Minjoung Park, Geon Kook Lee, Ji-Youn Han
Cancer Res Treat.2021;53(4):1024-1032.   Published online 2021 January 29     DOI: http://dx.doi.org/10.4143/crt.2020.1331
      
10 Delphinidin enhances radio-therapeutic effects via autophagy induction and JNK/MAPK pathway activation in non-small cell lung cancer
Seong Hee Kang, Dong-Ho Bak, Byung Yeoup Chung, Hyoung-Woo Bai, Bo Sun Kang
Korean J Physiol Pharmacol.2020;24(5):413-422.   Published online 2020 September 1     DOI: http://dx.doi.org/10.4196/kjpp.2020.24.5.413
      
11 Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee
Cancer Res Treat.2020;52(1):284-291.   Published online 2019 July 23     DOI: http://dx.doi.org/10.4143/crt.2019.200
      
12 SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer
Yoo-Kang Kwak, Hee Hyun Park, Kyu Hye Choi, Eun Young Park, Soo Yoon Sung, Sea-Won Lee, Ji Hyun Hong, Hyo Chun Lee, Ie Ryung Yoo, Yeon Sil Kim
Cancer Res Treat.2020;52(1):85-97.   Published online 2019 May 17     DOI: http://dx.doi.org/10.4143/crt.2019.007
      
13 Clinical Significance of Pleural Attachment and Indentation of Subsolid Nodule Lung Cancer
Hyung-Jun Kim, Jun Yeun Cho, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Jin-Haeng Chung, Sukki Cho, Kwhanmien Kim, Kyung Won Lee, Jae Ho Lee, Choon-Taek Lee
Cancer Res Treat.2019;51(4):1540-1548.   Published online 2019 March 25     DOI: http://dx.doi.org/10.4143/crt.2019.057
      
14 The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
Ji Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo
Cancer Res Treat.2019;51(1):169-177.   Published online 2018 April 5     DOI: http://dx.doi.org/10.4143/crt.2017.491
      
15 Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang
Cancer Res Treat.2018;50(3):835-842.   Published online 2017 August 29     DOI: http://dx.doi.org/10.4143/crt.2017.303
      
16 Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
Youngjoo Lee, Ki Hyeong Lee, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Yun Jung Go, Jin Soo Lee, Ji-Youn Han
Cancer Res Treat.2017;49(4):1001-1011.   Published online 2017 January 13     DOI: http://dx.doi.org/10.4143/crt.2016.546
      
17 Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
Keunchil Park, Eun Kyung Cho, Maximino Bello, Myung-Ju Ahn, Sumitra Thongprasert, Eun-Kee Song, Victoria Soldatenkova, Henrik Depenbrock, Tarun Puri, Mauro Orlando
Cancer Res Treat.2017;49(4):937-946.   Published online 2017 January 6     DOI: http://dx.doi.org/10.4143/crt.2016.423
      
18 Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
Youngjoo Lee, Ji-Youn Han, Sung Ho Moon, Byung-Ho Nam, Kun Young Lim, Geon Kook Lee, Heung Tae Kim, Tak Yun, Hye Jin An, Jin Soo Lee
Cancer Res Treat.2017;49(4):981-989.   Published online 2017 January 6     DOI: http://dx.doi.org/10.4143/crt.2016.522
      
19 ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer
Ji-Youn Han, Geon Kook Lee, Kun Young Lim, Young Ju Lee, Byung Ho Nam, Jin Soo Lee
Cancer Res Treat.2017;49(3):678-687.   Published online 2016 October 11     DOI: http://dx.doi.org/10.4143/crt.2016.365
      
20 A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Ji-Youn Han, Ki Hyeong Lee, Sang-We Kim, Young Joo Min, Eunkyung Cho, Youngjoo Lee, Soo-Hyun Lee, Hyae Young Kim, Geon Kook Lee, Byung Ho Nam, Hyesun Han, Jina Jung, Jin Soo Lee
Cancer Res Treat.2017;49(1):10-19.   Published online 2016 May 3     DOI: http://dx.doi.org/10.4143/crt.2016.058
      

 1 of 3